LAVA Therapeutics N.V. (LVTX) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts LVTX Hot Sheet
Join SI Premium – FREE
LAVA Therapeutics N.V. (NASDAQ: LVTX) reported Q3 EPS of ($0.46), $0.13 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on LAVA Therapeutics N.V. (LVTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- People Incorporated (PPLI) PT Lowered to $47 at Citizens - Shares Meaningfully Undervalue Business
- Mirum Pharmaceuticals (MIRM) PT Raised to $167 at Citizens - One of 'Favorite Rare Disease Names'
- Jefferies Starts Core & Main Inc. (CNM) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
